MwanzoNBIX • NASDAQ
add
Neurocrine Biosciences Inc
$ 125.39
Baada ya Saa za Kazi:(0.00%)0.00
$ 125.39
Imefungwa: 6 Jun, 20:00:00 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 124.61
Bei za siku
$ 124.08 - $ 126.81
Bei za mwaka
$ 84.23 - $ 157.98
Thamani ya kampuni katika soko
12.41B USD
Wastani wa hisa zilizouzwa
1.43M
Uwiano wa bei na mapato
42.50
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 572.60M | 11.12% |
Matumizi ya uendeshaji wa biashara | 276.50M | 13.74% |
Mapato halisi | 7.90M | -81.80% |
Kiwango cha faida halisi | 1.38 | -83.61% |
Mapato kwa kila hisa | 0.70 | -41.67% |
EBITDA | 31.30M | -71.93% |
Asilimia ya kodi ya mapato | 46.26% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 943.50M | -22.06% |
Jumla ya mali | 3.69B | 6.20% |
Jumla ya dhima | 1.15B | 6.05% |
Jumla ya hisa | 2.54B | — |
hisa zilizosalia | 98.97M | — |
Uwiano wa bei na thamani | 4.87 | — |
Faida inayotokana na mali | 1.60% | — |
Faida inayotokana mtaji | 1.94% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 7.90M | -81.80% |
Pesa kutokana na shughuli | 64.80M | -50.27% |
Pesa kutokana na uwekezaji | 14.20M | 125.82% |
Pesa kutokana na ufadhili | -117.90M | -268.67% |
Mabadiliko halisi ya pesa taslimu | -38.90M | -126.79% |
Mtiririko huru wa pesa | 28.91M | -88.50% |
Kuhusu
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1992
Makao Makuu
Tovuti
Wafanyakazi
1,800
